Stock listing
BOATS:CRIS Curis, Inc. Stock
US listing (BOATS) of Curis, Inc. · home listing NASDAQ:CRIS
Follow Curis, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CRIS
$0.427 USD -0.042 (-9.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRIS
- Day range
- $0.420 – $0.494 USDNov 20, 2026
- Volume
- 524,812 sharesNov 20, 2026
- Market cap
- $2.85M USDAt the close on Nov 20, 2026 · price × 6.68M shares outstanding
- 52-week range
- $0.330 – $28.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.95M USDMedian day 182,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRIS · Home | $0.427 USD | -0.042 (-9.0%) | 524,812 | $0.473 | $0.494 | $0.420 | $0.469 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRIS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.427 | -0.042 | -9.0% | $0.473 | $0.494 | $0.420 | 524,812 | |
| $0.469 | -0.145 | -23.6% | $0.592 | $0.605 | $0.460 | 1,258,887 | |
| $0.614 | +0.073 | +13.4% | $0.527 | $0.614 | $0.483 | 10,640,979 | |
| $0.542 | +0.106 | +24.3% | $0.471 | $0.550 | $0.449 | 12,675,005 | |
| $0.436 | -0.014 | -3.2% | $0.420 | $0.470 | $0.416 | 469,701 | |
| $0.450 | -0.120 | -21.1% | $0.500 | $0.500 | $0.430 | 720,500 | |
| $0.570 | -0.020 | -3.4% | $0.600 | $0.610 | $0.540 | 528,100 | |
| $0.590 | -0.060 | -9.2% | $0.640 | $0.660 | $0.560 | 513,100 | |
| $0.650 | -0.050 | -7.1% | $0.640 | $0.660 | $0.560 | 1,307,200 | |
| $0.700 | -0.210 | -23.1% | $0.890 | $0.900 | $0.680 | 1,742,200 | |
| $0.910 | +0.060 | +7.1% | $0.800 | $0.950 | $0.760 | 2,605,500 | |
| $0.850 | -0.260 | -23.4% | $0.990 | $1.090 | $0.830 | 11,916,900 | |
| $1.110 | +0.400 | +56.3% | $1.350 | $1.600 | $1.060 | 163,533,100 | |
| $0.710 | +0.050 | +7.6% | $0.720 | $1.500 | $0.620 | 51,139,200 | |
| $0.660 | +0.060 | +10.0% | $0.580 | $0.760 | $0.570 | 1,093,800 | |
| $0.600 | +0.050 | +9.1% | $0.550 | $0.650 | $0.470 | 913,200 | |
| $0.550 | +0.100 | +22.2% | $0.460 | $0.670 | $0.450 | 6,414,200 | |
| $0.450 | +0.050 | +12.5% | $0.410 | $0.450 | $0.400 | 252,200 | |
| $0.400 | +0.020 | +5.3% | $0.380 | $0.410 | $0.370 | 237,700 | |
| $0.380 | -0.010 | -2.6% | $0.410 | $0.410 | $0.360 | 315,500 | |
| $0.390 | -0.010 | -2.5% | $0.410 | $0.420 | $0.380 | 66,900 | |
| $0.400 | +0.010 | +2.6% | $0.400 | $0.410 | $0.380 | 157,900 | |
| $0.390 | -0.010 | -2.5% | $0.410 | $0.410 | $0.390 | 95,800 | |
| $0.400 | +0.020 | +5.3% | $0.370 | $0.410 | $0.370 | 217,100 | |
| $0.380 | -0.030 | -7.3% | $0.420 | $0.430 | $0.360 | 256,500 | |
| $0.410 | -0.100 | -19.6% | $0.450 | $0.450 | $0.330 | 1,338,600 | |
| $0.510 | -0.090 | -15.0% | $0.590 | $0.610 | $0.470 | 489,400 | |
| $0.600 | -0.010 | -1.6% | $0.620 | $0.620 | $0.570 | 123,000 | |
| $0.610 | -0.030 | -4.7% | $0.640 | $0.690 | $0.590 | 210,300 | |
| $0.640 | -0.030 | -4.5% | $0.680 | $0.690 | $0.630 | 127,800 | |
| $0.670 | -0.040 | -5.6% | $0.720 | $0.720 | $0.650 | 95,900 | |
| $0.710 | -0.030 | -4.1% | $0.710 | $0.820 | $0.610 | 426,500 | |
| $0.740 | -0.010 | -1.3% | $0.790 | $0.790 | $0.720 | 141,900 | |
| $0.750 | -0.040 | -5.1% | $0.770 | $0.770 | $0.730 | 181,900 | |
| $0.790 | -0.010 | -1.3% | $0.810 | $0.820 | $0.720 | 556,300 | |
| $0.800 | -0.030 | -3.6% | $0.840 | $0.840 | $0.800 | 100,200 | |
| $0.830 | -0.010 | -1.2% | $0.860 | $0.860 | $0.830 | 37,900 | |
| $0.840 | +0.010 | +1.2% | $0.830 | $0.860 | $0.830 | 92,200 | |
| $0.830 | 0.000 | 0.0% | $0.820 | $0.840 | $0.800 | 165,500 | |
| $0.830 | 0.000 | 0.0% | $0.840 | $0.860 | $0.800 | 158,300 | |
| $0.830 | -0.050 | -5.7% | $0.900 | $0.960 | $0.810 | 286,100 | |
| $0.880 | -0.070 | -7.4% | $0.970 | $0.990 | $0.860 | 308,400 | |
| $0.950 | -0.050 | -5.0% | $1.000 | $1.010 | $0.940 | 138,100 | |
| $1.000 | +0.030 | +3.1% | $0.980 | $1.070 | $0.970 | 159,200 | |
| $0.970 | -0.030 | -3.0% | $1.040 | $1.070 | $0.950 | 183,700 | |
| $1.000 | -0.090 | -8.3% | $1.110 | $1.130 | $1.000 | 121,500 | |
| $1.090 | -0.030 | -2.7% | $1.120 | $1.180 | $1.070 | 138,600 | |
| $1.120 | -0.010 | -0.9% | $1.080 | $1.150 | $1.070 | 180,000 | |
| $1.130 | +0.010 | +0.9% | $1.120 | $1.210 | $1.080 | 156,700 | |
| $1.120 | -0.010 | -0.9% | $1.160 | $1.190 | $1.110 | 134,100 | |
| $1.130 | -0.030 | -2.6% | $1.180 | $1.250 | $1.130 | 131,100 | |
| $1.160 | -0.040 | -3.3% | $1.210 | $1.240 | $1.110 | 146,600 | |
| $1.200 | -0.070 | -5.5% | $1.340 | $1.340 | $1.180 | 188,400 | |
| $1.270 | -0.080 | -5.9% | $1.320 | $1.350 | $1.260 | 144,500 | |
| $1.350 | -0.020 | -1.5% | $1.370 | $1.390 | $1.300 | 96,900 | |
| $1.370 | -0.010 | -0.7% | $1.420 | $1.420 | $1.350 | 126,000 | |
| $1.380 | -0.040 | -2.8% | $1.460 | $1.480 | $1.380 | 85,300 | |
| $1.420 | -0.070 | -4.7% | $1.450 | $1.470 | $1.400 | 65,100 | |
| $1.490 | 0.000 | 0.0% | $1.480 | $1.530 | $1.410 | 35,800 | |
| $1.490 | -0.010 | -0.7% | $1.510 | $1.580 | $1.450 | 119,300 | |
| $1.500 | -0.040 | -2.6% | $1.560 | $1.590 | $1.400 | 287,400 | |
| $1.540 | -0.050 | -3.1% | $1.590 | $1.610 | $1.510 | 105,400 | |
| $1.590 | +0.010 | +0.6% | $1.610 | $1.640 | $1.550 | 142,400 | |
| $1.580 | 0.000 | 0.0% | $1.600 | $1.650 | $1.510 | 82,800 | |
| $1.580 | -0.030 | -1.9% | $1.630 | $1.660 | $1.500 | 211,600 | |
| $1.610 | -0.110 | -6.4% | $1.710 | $1.720 | $1.590 | 133,500 |
Splits
2 splits since 2018 · NASDAQ:CRIS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-5 | Consolidation |
- Ticker
- BOATS:CRIS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Curis Provides Third Quarter 2026 Business Update
Latest earnings call · Nov 12, 2026
Curis (NASDAQ:CRIS) Q3 2026 Earnings Call
Replay and transcript
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 31 slides
Latest news
Curis Provides Third Quarter 2026 Business Update
Nov 12, 2026
Closed $0.45 (-21.1%) on Nov 13, 2026
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
Nov 5, 2026
Closed $0.91 (+7.1%) on Nov 6, 2026
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
Oct 16, 2026
Closed $0.41 (-19.6%) on Oct 16, 2026
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
Aug 13, 2026
Closed $1.87 (+12.0%) on Aug 13, 2026
Curis Doses First Five Patients in TakeAim CLL Study
Jul 30, 2026
Closed $4.96 (-0.4%) on Jul 30, 2026
Curis Announces Positive Emavusertib Update
Jul 22, 2026
Closed $4.94 (+4.0%) on Jul 22, 2026
Curis Consents First Six Patients in TakeAim CLL Study
Jul 6, 2026
Closed $5.94 (-15.1%) on Jul 6, 2026
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Jun 26, 2026
Closed $6.40 (+52.4%) on Jun 26, 2026
Curis Provides First Quarter 2026 Business Update
May 12, 2026
Closed $10.00 (-9.1%) on May 13, 2026
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
May 5, 2026
Closed $12.40 (+8.8%) on May 6, 2026
Curis, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 116 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 12, 2026
- Decks
- 79 decks · latest July 2026
Where Curis, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRIS · Home listing | NASDAQ | United States | USD |
| gettex:CUS0 | gettex | Germany | EUR |
| Lang & Schwarz:A3ETJD | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3ETJD | LS Exchange | Germany | EUR |
| BOATS:CRIS · This page | BOATS | United States | USD |
| Stuttgart:CUS0 | Stuttgart | Germany | EUR |
| Dusseldorf:CUS0 | Dusseldorf | Germany | EUR |
| Tradegate:CUS0 | Tradegate | Germany | EUR |
| Frankfurt:CUS0 | Frankfurt | Germany | EUR |
| Hamburg:CUS0 | Hamburg | Germany | EUR |
| Munich:CUS0 | Munich | Germany | EUR |
Valuation
Price/book 1.1× against a median of 1.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$1.42M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.85
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Curis, Inc. · NASDAQ:CRIS | US$2.85M | −US$1.42M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | 1.85 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Imunon, Inc. · NASDAQ:IMNN | US$3.00M | US$5.90M | n/a | n/a | n/a | 1.1× | n/a | 2.6× | 0.57 |
| Gelteq Limited · NASDAQ:GELS | US$2.89M | US$6.27M | n/a | 57.2× | n/a | 0.3× | n/a | 0.4× | 0.83 |
| Fluicell AB · OMXSTO:FLUI | US$2.83M | US$3.03M | 10.4× | 1.6× | 10.7× | 1.8× | 14.1% | 0.1× | n/a |
| Alligator Bioscience AB · OMXSTO:ATORX | US$2.79M | US$1.47M | n/a | 53.3× | n/a | 1.2× | n/a | 1.2× | n/a |
| Traws Pharma, Inc. · NASDAQ:TRAW | US$2.69M | US$351,448 | n/a | n/a | n/a | n/a | n/a | n/a | 2.07 |
| NextCell Pharma AB · OMXSTO:NXTCL | US$2.69M | US$626,140 | n/a | 0.6× | n/a | 0.6× | −440.8% | 0.0× | n/a |
| Bioxytran, Inc. · OTC:BIXT | US$2.66M | US$2.59M | n/a | n/a | n/a | n/a | n/a | n/a | -1.20 |
| Median of the others | US$2.86M | US$1.47M | 10.4× | 1.6× | 10.7× | 1.1× | −213.3% | 0.1× | 0.85 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 42.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -32.48 · 1 analyst
- Revenue, year to Dec 2026
- 1.75M · 4 analysts
Team and board
| Officer | Role |
|---|---|
| James Dentzer | President & CEO |
| Diantha Duvall | Chief Financial Officer |
| Maureen E. Lane | Vice President, Clinical and Translational Science |
| Nick Pelletier | Vice President, Clinical Operations |
| Ahmed Hamdy | Chief Medical Officer |
| Jonathan Zung | Chief Development Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Curis (NASDAQ:CRIS) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 4:30 PM ET | Replay |
| Curis (NASDAQ:CRIS) Q1 2026 Earnings Call | Tue, May 12, 2026 · 4:30 PM ET | Replay |
| Curis (NASDAQ:CRIS) Q4 2025 Earnings Call | Thu, Mar 19, 2026 · 4:30 PM ET | Replay |
| Curis (NASDAQ:CRIS) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 4:30 PM ET | Replay |
| Curis (NASDAQ:CRIS) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 8:30 AM ET | Replay |
| Curis (NASDAQ:CRIS) Q1 2025 Earnings Call | Tue, May 06, 2025 · 8:30 AM ET | Replay |
| Curis (NASDAQ:CRIS) Q4 2024 Earnings Call | Mon, Mar 31, 2025 · 8:30 AM ET | Replay |
| Curis (NASDAQ:CRIS) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:30 AM ET | Replay |
| Curis (NASDAQ:CRIS) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 8:30 AM ET | Replay |
| Curis (NASDAQ:CRIS) Q1 2024 Earnings Call | Tue, May 07, 2024 · 8:30 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −21.1% |
| Q2 2026 | Aug 14, 2026 · After close | 0.0% |
| Q1 2026 | May 12, 2026 · After close | −9.1% |
| Q4 2025 | Mar 20, 2026 | −2.6% |
| Q3 2025 | Nov 6, 2025 · After close | −10.3% |
| Q2 2025 | Aug 5, 2025 · Before open | +4.4% |
| Q1 2025 | May 6, 2025 · Before open | −10.6% |
| Q4 2024 | Mar 31, 2025 | −37.1% |
| Q3 2024 | Nov 14, 2024 · Before open | +1.3% |
| Q2 2024 | Aug 1, 2024 · Before open | −9.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | +0.2% |
| Q4 2023 | Feb 8, 2024 · Before open | +13.4% |
| Q3 2023 | Nov 2, 2023 · Before open | −4.3% |
| Q2 2023 | Aug 3, 2023 · After close | −9.1% |
| Q1 2023 | May 4, 2023 · After close | −3.6% |
| Q4 2022 | Mar 13, 2023 · Before open | −7.9% |
| Q3 2022 | Nov 9, 2022 · After close | +13.9% |
| Q2 2022 | Aug 4, 2022 · After close | +1.0% |
| Q1 2022 | May 5, 2022 · After close | −4.4% |
| Q4 2021 | Feb 24, 2022 · After close | +0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 31 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 31 slides | June 2026 |
| Q1 2026 Earnings Presentation | Earnings | 32 slides | May 12, 2026 |
| Investor Presentation (May 2026) | Investor deck | 32 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 32 slides | March 2026 |
| Investor Presentation (November 2025) | Investor deck | 31 slides | November 2025 |
| Investor Presentation (October 2025) | Investor deck | 30 slides | October 2025 |
| Investor Presentation (September 2025) | Investor deck | 31 slides | September 2025 |
| Investor Presentation (July 2025) | Investor deck | 31 slides | July 2025 |
| Q1 2025 Earnings Presentation | Earnings | 40 slides | May 6, 2025 |
Show 50 decks
This page holds 50 of 79 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants Announced: about US$8.5M · US$0.51 a share · ½ warrant at US$0.6 for 66 months · A.G.P./Alliance Global Partners +1 Dealers: A.G.P./Alliance Global Partners (lead), Laidlaw & Company (UK) Ltd. Use of proceeds: Research and development, working capital and general corporate purposes | Oct 16, 2026 |
| Public offering of common stock (or pre-funded warrants) and accompanying common warrants Announced: about US$5.6M · US$1.5 a share · Warrants at US$1.75 for 60 months · A.G.P./Alliance Global Partners +1 Dealers: A.G.P./Alliance Global Partners (lead), Laidlaw & Company (UK) Ltd. Use of proceeds: Fund research and development activities, working capital and general corporate purposes | Aug 13, 2026 |
| Private placement of private placement (PIPE financing) Closed: US$20.2M raised · US$1,000 a share · Warrants at US$0.75 · Laidlaw & Company (UK) Ltd. Dealers: Laidlaw & Company (UK) Ltd. (lead) Buyers: Nantahala Capital; Stonepine Capital Management; Pointillist Partners, LLC; The Red Hook Fund, LP Insiders: Members of the Company's management team and board of directors participated. Use of proceeds: Research and development, general corporate expenses and working capital | Jan 9, 2026 |
| Registered direct offering of common stock, with concurrent private placement of pre-funded and common warrants Announced: about US$7M · US$2.275 a share · Warrants at US$2.15 for 60 months · Laidlaw & Company (U.K.) Ltd. +1 Dealers: Laidlaw & Company (U.K.) Ltd., Jones Use of proceeds: Research, development, working capital and other general corporate purposes | Jul 2, 2025 |
| Registered direct offering of common stock, with concurrent private placement Closed: US$8.8M raised Use of proceeds: To fund planned operations into the fourth quarter of 2025 | May 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.44M | 10.9M | 10.0M | 10.2M | 10.6M | 10.8M | 10.0M | 10.4M | 9.90M | 7.53M |
| Cost of revenue | 45.0K | 98.0K | 229.0K | 257.0K | 533.0K | 534.0K | 503.0K | 563.0K | 496.0K | 399.0K |
| Gross profit | 9.40M | 10.8M | 10.0M | 9.90M | 10.1M | 10.3M | 9.50M | 9.87M | 9.40M | 7.13M |
| Research and development | 28.3M | 38.6M | 39.5M | 43.3M | 34.9M | 23.1M | 22.3M | 24.4M | 45.1M | 18.0M |
| Selling, general and administrative | 14.0M | 16.8M | 18.6M | 19.6M | 17.3M | 12.1M | 11.6M | 14.8M | 25.8M | 15.6M |
| Operating income | -5.71M | -44.5M | -48.3M | -53.0M | -42.1M | -24.9M | -24.4M | -29.3M | -49.8M | -58.0M |
| Depreciation and amortization | 169.0K | 203.0K | 255.0K | 233.0K | 158.0K | 144.0K | 125.0K | 177.0K | 235.0K | 193.0K |
| EBITDA | -5.54M | -44.3M | -48.1M | -52.8M | -41.9M | -24.8M | -24.2M | -29.2M | -49.5M | -57.8M |
| Interest expense | 2.19M | 615.0K | 2.02M | 4.77M | 0 | 0 | 791.0K | 3.93M | 3.97M | 2.78M |
| Income before tax | -7.58M | -43.4M | -47.4M | -56.7M | -45.4M | -29.9M | -32.1M | -32.6M | -53.3M | -60.4M |
| Income tax | 0 | 0 | -255.0K | 3.65M | 5.20M | 4.97M | 4.66M | 683.0K | 3.86M | 2.58M |
| Net income | -7.58M | -43.4M | -47.4M | -56.7M | -45.4M | -29.9M | -32.1M | -32.6M | -53.3M | -60.4M |
| Earnings per share, basic | -0.58 | -6.88 | -8.96 | -12.14 | 0.50 | -0.61 | -0.97 | -0.98 | -1.79 | -0.45 |
| Earnings per share, diluted | -0.58 | -6.88 | -8.96 | -12.14 | 0.50 | -0.61 | -0.97 | -0.98 | -1.79 | -0.45 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.06M | 20.0M | 26.7M | 19.7M | 40.0M | 129.6M | 15.4M | 23.6M | 38.3M | 26.0M |
| Short-term investments | 0 | 29.7M | 66.0M | 75.9M | 38.9M | 5.11M | 634.0K | 21.9M | 18.4M | |
| Receivables | 0 | 3.35M | 2.79M | 2.98M | 3.22M | 3.04M | 3.24M | 2.86M | 3.07M | 2.46M |
| Inventory | -2.89M | -2.89M | -2.54M | -399.0K | -94.0K | -827.0K | 0 | -1.26M | ||
| Current assets | 6.92M | 26.4M | 60.9M | 92.1M | 122.4M | 172.8M | 25.0M | 28.0M | 64.3M | 48.2M |
| Property, plant and equipment | 62.0K | 231.0K | 434.0K | 689.0K | 505.0K | 663.0K | 154.0K | 267.0K | 366.0K | 413.0K |
| Goodwill | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M |
| Total assets | 20.0M | 41.3M | 77.3M | 108.8M | 162.3M | 204.4M | 35.1M | 37.4M | 73.8M | 57.8M |
| Accounts payable | 5.61M | 3.02M | 3.17M | 3.19M | 6.42M | 4.17M | 4.46M | 2.91M | 5.42M | 5.88M |
| Current liabilities | 14.1M | 19.0M | 22.0M | 10.0M | 13.4M | 10.1M | 6.54M | 13.3M | 14.1M | 13.5M |
| Long-term debt | 334.0K | 0 | 28.6M | 35.7M | 14.9M | |||||
| Total debt | 0 | 7.56M | 8.50M | 6.74M | 0 | 891.0K | 0 | 35.5M | 41.6M | 19.9M |
| Total liabilities | 14.5M | 47.3M | 57.6M | 62.3M | 71.6M | 73.7M | 69.0M | 41.9M | 49.8M | 28.5M |
| Shareholders' equity | 5.46M | -6.00M | 19.7M | 46.6M | 90.7M | 130.7M | -33.9M | -4.50M | 24.0M | 29.5M |
| Shares outstanding | 646.5K | 8.49M | 5.89M | 4.83M | 91.6M | 91.5M | 33.2M | 33.2M | 32.8M | 141.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -27.2M | -39.6M | -38.4M | -54.3M | -37.6M | -25.7M | -26.2M | -30.1M | -48.4M | -35.8M |
| Capital spending | 0 | 0 | 0 | -416.0K | 0 | -677.0K | -41.0K | -85.0K | -188.0K | -329.0K |
| Free cash flow | -27.2M | -39.6M | -38.4M | -54.8M | -37.6M | -26.4M | -26.2M | -30.1M | -48.5M | -36.1M |
| Cash from investing | 2.50M | 29.4M | 37.8M | 33.0M | -47.9M | -49.0M | -4.46M | 21.4M | -3.63M | 30.1M |
| Cash from financing | 9.77M | 3.44M | 7.58M | 867.0K | -4.17M | 188.8M | 23.3M | -5.96M | 64.2M | -1.37M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 5.84M | 300.0K | 158.7M | 68.0K | 143.0K | 42.7M | 2.91M | |||
| Change in cash | -14.9M | -6.68M | 6.93M | -20.4M | -89.7M | 114.0M | -7.39M | -14.7M | 12.3M | -7.05M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| S-8 POS | Nov 13, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2026 | Offer document | SEC |
| S-3 · Registration statement | Nov 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 2, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 424B4 · Prospectus | Aug 13, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2026 | Other filings | SEC |
| S-1 · Registration statement | Aug 10, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| DRS · Draft registration statement | Jul 17, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jun 25, 2026 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jun 5, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 22, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 8-K · Current report | May 1, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 24, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 27, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 23, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2026 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Mar 17, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Feb 19, 2026 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Feb 19, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Feb 13, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Feb 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 7, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Nov 13, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Nov 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| 8-K · Current report | Aug 22, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 19, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Aug 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 424B5 · Prospectus | Aug 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 424B5 · Prospectus | Jul 2, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Jul 2, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 2, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 8-K · Current report | May 22, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 15, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | May 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 16, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 31, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 31, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 424B5 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Mar 28, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 28, 2025 | Results | SEC |
| 8-K · Current report | Feb 27, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jan 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 31, 2024 | Other filings | SEC |
| S-3 · Registration statement | Dec 23, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 1, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Oct 30, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2024 | Material contract | SEC |
| FWP · Free writing prospectus | Oct 28, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Jun 14, 2024 | Offer document | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 23, 2024 | Management or board change | SEC |
| 8-K · Current report | May 14, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Apr 15, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 10, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 29, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 13, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Feb 12, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 8, 2024 | Offer document | SEC |
| S-3 · Registration statement | Feb 8, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 8, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 8, 2024 | Results | SEC |
| 8-K · Current report | Jan 11, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jan 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 21, 2023 | Other filings | SEC |
| 10-K/A · Annual report, amended | Dec 21, 2023 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Dec 12, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 8-K/A · Current report, amended | Sep 28, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Sep 28, 2023 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Aug 18, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 4, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 424B5 · Prospectus | Jul 6, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 6, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 6, 2023 | Current report | SEC |
| 8-K · Current report | May 30, 2023 | Meeting outcome | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Curis, Inc.’s releases · as of Oct 16, 2026
- Common shares
- 6,679,229
- Fully diluted
- 6,699,424
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,679,229 | |
| Warrants | 20,195 | Jan 8, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.75 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 6,679,229 |
| Jun 26, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Hohneker Other companies: ArriVent BioPharma, Inc. (Director · Since at least May 16, 2024); Carisma Therapeutics, Inc. (Director · Apr 1, 2024 – Jun 26, 2024 · Past); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past) | Director · Since at least Dec 2, 2021 |
| Lori Kunkel Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); ORIC Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2020); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 19, 2025 · Past); Tocagen Inc (Director · Jun 21, 2018 – Oct 4, 2019 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past) | Director · Jan 22, 2018 – Jan 31, 2022 · Past |
| Mani Mohindru Other companies: Cardiff Oncology, Inc. (President & Chief Executive Officer · Since at least Jun 10, 2021); CytomX Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Tvardi Therapeutics, Inc. (CFO & Chief Strategy Officer · Aug 15, 2017 – Dec 2, 2019 · Past) | Chief Strategy Officer · Jan 19, 2016 – Feb 14, 2017 · Past |
| Anne Borgman Other companies: NextCure, Inc. (Director · Since at least Jun 23, 2022); Sutro Biopharma, Inc. (CHIEF MEDICAL OFFICER · Feb 28, 2023 – May 1, 2025 · Past) | Director · Since at least Oct 12, 2022 |
| Joseph Md Phd Davie Other companies: Armata Pharmaceuticals, Inc. (Director · May 8, 2006 – May 29, 2009 · Past); CV Therapeutics Inc (Director · Jan 13, 2006 – Apr 14, 2009 · Past) | Director · Jan 25, 2008 – Jan 7, 2011 · Past |
| Ahmed Hamdy Other companies: Vincerx Pharma Inc (Chief Executive Officer, Director · Jun 29, 2021 – Aug 12, 2024 · Past) | Chief Medical Officer · Since at least May 1, 2025 |
| James Dentzer Other companies: Imunon, Inc. (Director · Since at least Sep 29, 2022) | President & CEO, Director · Since at least Jan 20, 2023 |
| Jonathan Zung Other companies: Evelo Biosciences, Inc. (Chief Development Officer · Jan 4, 2021 – Jul 19, 2022 · Past) | Chief Development Officer · Since at least May 1, 2023 |
| Kenneth Pienta Other companies: Cue Biopharma, Inc. (Chief Medical Officer · Dec 18, 2017 – Mar 25, 2022 · Past) | Director · Mar 7, 2013 – Feb 28, 2017 · Past |
| Robert Martell Other companies: Indaptus Therapeutics, Inc. (Director · Since at least Feb 13, 2023) | Head of Research & Development · Sep 14, 2011 – Jan 20, 2023 · Past |
All 23 people
| Person | Seat |
|---|---|
| Stephen Carter Other companies: Vion Pharmaceuticals Inc (Director · Jun 27, 2007 – Jun 27, 2007 · Past) | Director · Dec 17, 2007 – Jan 25, 2008 · Past |
| Ali Ph D Fattaey | President & CEO, Director · Feb 19, 2013 – May 15, 2018 · Past |
| Changgeng Qian | VP, Research & Preclinical Dev · Oct 24, 2008 – Jan 7, 2011 · Past |
| Diantha Duvall | CFO · Since at least Aug 5, 2022 |
| Joseph M Davie | Director · Jun 1, 2006 – Jun 6, 2007 · Past |
| Kenneth I Kaitin | Director · Since at least Mar 31, 2026 |
| Marc Rubin | Director · Since at least May 20, 2025 |
| Martyn D Greenacre | Director · Since at least May 21, 2024 |
| Mary Elizabeth Potthoff | VP and General Counsel · May 31, 2006 – May 31, 2006 · Past |
| Maureen E. Lane | Vice President, Clinical and Translational Science · Since at least Nov 4, 2026 |
| Mitchell Keegan | Vice-President · Sep 2, 2009 – Jan 7, 2011 · Past |
| Nick Pelletier | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| William Steinkrauss | Chief Financial Officer · Sep 10, 2019 – Jan 29, 2022 · Past |
Log in to ask 6ix AI your own questions about Curis, Inc.